Addyi The Pink Viagra aka Woman Savior Is here

Have a Low Sex Drive? The FDA Just Approved a Drug For You

Katie Holmes Flashes Butt Cheeks in anticipation of Addyi The Pink Viagra …

Gone off sex? Never fear, ‘pink Viagra’ is here to save womankind
The holy grail of the drugs industry has arrived. Women who mostly can’t be bothered with sex can take a pill that will make them crave it – even with their own partners
Rejoice, rejoice womankind! There is now a magic drug that will make sex desirable.
Poppy Montgomery … Pink Assssss

Viagra is so late-’90s — women everywhere, get ready to get some. The FDA has approved the first prescription libido-boosting drug for women, Addyi from Sprout Pharmaceuticals, and it’s kind of a big deal. Of course there are plenty of comparisons being made between the “little pink pill” and the “little blue pill,” but as The New York Times points out, Addyi is “actually the first drug approved to treat a flagging or absent libido for either sex.” While “Viagra and other drugs available for men are approved to help achieve erections, or to treat certain deficiencies of the hormone testosterone, not to increase desire.”
Again. Or for the first time. I can’t name here the already-existing drugs that have such an effect because they are illegal, and who knows what would happen if people took them? (In fact, they have done for decades.) But, never mind, this new magic drug has just been legalised in the US, having been approved by the US Food and Drugs Administration. Flibanserin has just passed an FDA advisory committee stage at the third attempt, so will soon be on the market. It will be sold as Addyi and is produced by Sprout Pharmaceuticals, which has been pushing what has been dubbed “the female Viagra” for some time.
The tablets are, of course, pink because women like pink pills and not blue smarties as we are silly like that. ‘Pink Viagra’ has been the holy grail of the drugs industry. Let’s face it, it’s the holy grail of all kinds of cultural imaginings: the magic substance that makes women who mostly can’t be that bothered with sex suddenly crave it. Even with their own partners! No drug can guarantee this, obviously. Years ago, when I worked in a health food shop in Manhattan, I was always shocked by the number of men who asked me to sell them something to: “Make my wife … you know? Like it.” But I still flogged them any old combination of herbs and vitamins because I was working on commission. I was hard of heart and short of money.
How does it work?

Addyi, known generically as flibanserin, acts on brain chemicals associated with mood and appetite, similar to antidepressant drugs. It was originally studied as a treatment for depression before being repurposed into a libido drug. It’s not entirely clear why the drug increases sexual desire but researchers point to its ability to increase dopamine — a brain chemical associated with appetite — while lowering serotonin — another chemical linked with feelings of satiation.

Experts usually describe Addyi’s effect as “modest.” In company studies, women taking flibanserin reported a slight increase in sexually satisfying events each month. Their answers to separate questionnaires indicated they experienced a slight increase in desire and a slight decrease in stress.

While FDA scientists describe these effects as “small,” they were significant enough to meet FDA effectiveness standards.

How much will it cost?

Sprout says women who have health insurance will pay between $30 and $75 for a month’s supply of Addyi, depending on their coverage terms.

Who will take this drug?

The U.S. FDA approved Addyi for premenopausal women with hypoactive sexual desire disorder, described as a lack of sexual appetite that causes emotional distress.

Surveys estimate that between 5.5 million to 8.6 million U.S. women have the condition, or roughly 8 to 14 per cent of women ages 20 to 49. Because so many other factors affect sexual appetite, there are a number of alternate causes doctors must rule out before diagnosing the condition, including relationship problems, medical conditions and mood issues caused by other medications like sleeping aids and painkillers.

The diagnosis is not universally accepted and many psychologists argue that low sex drive should not be considered a medical condition.

I’ve heard this decision was controversial, why?

The drug followed a long, contentious path to approval, including two previous rejections by the FDA. For years, two opposing sides have argued over the fate of the drug.

On one hand, drug makers and some medical experts argue that women need FDA-approved medications to treat sexual disorders, which they consider serious medical problems. On the other side, consumer-safety advocates have said the drug’s side effects are too risky, and there are those who question whether low libido is a medical condition.

On top of this debate, Sprout Pharmaceuticals enlisted outside politicians and women’s groups to lobby the FDA to approve the drug.

What are the side effects?

About 10 per cent of patients in Sprout’s studies experienced the most common problems: dizziness, fatigue and nausea. The drug will also bear a boxed warning that women should not drink alcohol or take certain types of other medications, including antifungal drugs, because of an interaction that can cause low blood pressure and fainting.

Why did the FDA approve Addyi this time around?

When U.S. FDA regulators first rejected Addyi in 2010 they noted that the drug failed to achieve a key study goal — increasing desire based on patients’ daily journal entries. Because of that lack of effectiveness, they said, the drug’s negative side effects outweighed its benefits.

Since then, Sprout conducted another study of sexual desire using a different method that achieved statistical significance. The company also conducted several safety studies to more clearly define the drug’s risks, which are outlined in its warning label.

While the FDA is required to make all decisions based on science, critics say that the concerted lobbying effort by Sprout-funded supporters also played a role in Addyi’s approval.

When will the drug be available?

Sprout plans to launch the drug in mid-October.

Celebs are warming up for action. First, the warm up their Ass …
Dakota Fanning